



University of Dundee

Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress

Krzemień, Paweł; Kasperczyk, Sławomir; Banach, Maciej; Kasperczyk, Aleksandra; Dobrakowski, Michał; Tomasik, Tomasz

Published in:
Biomarker Insights

DOI:
[10.1177/11772719211066791](https://doi.org/10.1177/11772719211066791)

Publication date:
2022

Licence:
CC BY-NC

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Krzemień, P., Kasperczyk, S., Banach, M., Kasperczyk, A., Dobrakowski, M., Tomasik, T., Windak, A., Mastej, M., Catapano, A., Ray, K. K., Mikhailidis, D. P., Toth, P. P., Howard, G., Lip, G. Y., Tomaszewski, M., Charchar, F. J., Sattar, N., Williams, B., MacDonald, T. M., ... Józwiak, J. J. (2022). Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. *Biomarker Insights*, 17, 1-12. <https://doi.org/10.1177/11772719211066791>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress

Paweł Krzemięń¹, Sławomir Kasperczyk², Maciej Banach³, Aleksandra Kasperczyk², Michał Dobrakowski², Tomasz Tomasik⁴, Adam Windak⁴, Mirosław Mastej⁵, Alberico Catapano⁶, Kausik K Ray⁷, Dimitri P Mikhailidis⁸, Peter P Toth^{9,10}, George Howard¹¹, Gregory YH Lip^{12,13}, Maciej Tomaszewski¹⁴, Fadi J Charchar¹⁵, Naveed Sattar¹⁶, Bryan Williams¹⁷, Thomas M MacDonald¹⁸, Peter E Penson¹⁹ and Jacek J Józwiak²⁰ on behalf of the LIPIDOGRAM2015 Investigators**

¹Euroimmun Polska Sp. z o.o., Wrocław, Poland. ²Department of Biochemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. ³Department of Hypertension, Medical University of Łódź, Łódź, Poland. ⁴Department of Family Medicine, Jagiellonian University Medical College, Krakow, Poland. ⁵Mastej Medical Center, Jasto, Poland. ⁶Department of Pharmacological Sciences, University of Milano and Multimedica IRCCS, Milano, Italy. ⁷Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, Imperial College, Kensington, London, UK. ⁸Department of Clinical Biochemistry, Royal Free Hospital, University College London, London, UK. ⁹Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ¹⁰CGH Medical Center, Sterling, IL, USA. ¹¹Department of Biostatistics, School of Public Health of Alabama at Birmingham, Birmingham, AL, USA. ¹²Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. ¹³Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. ¹⁴Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. ¹⁵School of Health and Life Sciences, Federation University Australia, Ballarat, VIC, Australia. ¹⁶Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK. ¹⁷NIHR University College London Biomedical Research Centre, University College London and University College London Hospitals NHS Foundation Trust, London, UK. ¹⁸MEMO Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. ¹⁹Liverpool Centre for Cardiovascular Science, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK. ²⁰Department of Family Medicine and Public Health, Faculty of Medicine, University of Opole, Opole, Poland.

Biomarker Insights
Volume 17: 1–12
© The Author(s) 2022
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/11772719211066791



ABSTRACT

BACKGROUND: The anti-DFS70 autoantibodies are one of the most commonly and widely described agent of unknown clinical significance, frequently detected in healthy individuals. It is not known whether the DFS70 autoantibodies are protective or pathogenic. One of the factors suspected of inducing the formation of anti-DFS70 antibodies is increased oxidative stress. We evaluated the coexistence of anti-DFS70 antibodies with selected markers of oxidative stress and investigated whether these antibodies could be considered as indirect markers of oxidative stress.

METHODS: The intensity of oxidative stress was measured in all samples via indices of free-radical damage to lipids and proteins such as total oxidant status (TOS), concentrations of lipid hydroperoxides (LPH), lipofuscin (LPS), and malondialdehyde (MDA). The parameters of the non-enzymatic antioxidant system, such as total antioxidant status (TAS) and uric acid concentration (UA), were also measured, as well as the activity of superoxide dismutase (SOD). Based on TOS and TAS values, the oxidative stress index (OSI) was calculated. All samples were also tested with indirect immunofluorescence assay (IFA) and 357 samples were selected for direct monospecific anti DFS70 enzyme-linked immunosorbent assay (ELISA) testing.

RESULTS: The anti-DFS70 antibodies were confirmed by ELISA test in 21.29% of samples. Compared with anti-DFS70 negative samples we observed 23% lower concentration of LPH ($P = .038$) and 11% lower concentration of UA ($P = .005$). TOS was 20% lower ($P = .014$). The activity of SOD was up to 5% higher ($P = .037$). The Pearson correlation showed weak negative correlation for LPH, UA, and TOS and a weak positive correlation for SOD activity.

CONCLUSION: In samples positive for the anti-DFS70 antibody a decreased level of oxidative stress was observed, especially in the case of samples with a high antibody titer. Anti-DFS70 antibodies can be considered as an indirect marker of reduced oxidative stress or a marker indicating the recent intensification of antioxidant processes.

KEYWORDS: Antibodies, oxidative stress, free radicals, biomarkers



RECEIVED: July 29, 2021. ACCEPTED: November 19, 2021.

**** LIPIDOGRAM2015 & LIPIDOGEN2015 INVESTIGATORS**

Al-Shaer B., Andruszewicz W., Andrzejczuk-Rosa M., Anusz-Gaszewska E., Bagińska A., Balawajder P., Bańka G., Barańska-Skubisz E., Barbara Przyczyna B., Bartkowiak S., Bartodziej J., Bartosiewicz M., Basałyga M., Batory A., Bąk A., Bednarz M., Bejnar K., Bernacki W., Betliuk-Kwiatkowska M., Biegaj S., Biełł M., Bilski W., Biłogon M., Biruta-Pawłowska G., Biskup A., Błaszczak B., Błaszczak H., Błonska-Jankowska T., Bogacka-Gancarczyk B., Bojanowska M., Bondy E., Borowik-Skwarek J., Borowska J., Bruckner J., Brzostek J., Brzuchacz M., Budzińska M., Bulzacka-Fugiel I., Bulzak J., Bunikowski K., Cebulska A., Celka T., Cempel-Nowak E., Chechliński W., Chludzińska A., Chmiel D., Chmielewska M., Cichy M., Ciemięga A., Cieluch A., Cieszyńska I., Czajka B., Czapla B., Czerner M., Czerwińska B., Czuryżkiewicz W., Daleka E., Dawid Z., Dąbrowska M., Dąbrowska R., Dąbrowski D., Dąbrowski M., Demczyszyn K., Dębowska-Serwińska A., Dmochowski J., Dobrzecka-Kiwior J., Dolanowska E., Dolanowski H., Dołek P., Domagała M., Domański H., Doszel A., Duda D., Dudkowska M., Dudziuk B., Dybciak P., Dymanowski M., Dziadzio-Bolek L., Eicke M., El-Hassan H., Eremus A., Faferek-Muller M., Figura-Roguska E., Fijałkowska-Kaczmarek I., Flis M., Florczak T., Florczuk M., Forszewska-Witan E., Frydrych W., Fugiel A., Futyma E., Gaca-Jaroszewicz A., Gajdamowicz I., Ganczarski K., Gatnar A., Gers M., Głowacki A., Głód K., Godula J., Gołąb J., Gołębiowski M., Goszczyńska E., Gościńska K., Górna-Hajduga A., Górny E., Grabowska T., Grabowski R., Graczyk-Duda A., Gromow A., Grudewicz A., Gruszecka J., Gruszka A., Gryboś J., Grzebyk J., Grzechowiak A., Grzesiak D., Grzeszowski T., Guźla A., Hachula G., Hawel B., Hiltawska H., Honkiewicz E., Ignatowicz J., Imielski K., Iwaniura A., Jagiela-Szymala A., Jałć-Sowata M., Janczylik A., Janisz E., Janiszek M., Jankiewicz-Ziobro K., Januszewska K., Jaremek A., Jaros-Urbaniak A., Jarosz J., Jarosz P., Jasiński W., Jezierska-Wasilewska M., Jędraszewski T., Jędrzejowska A., Józefowicz R., Juźwin K., Kacprzak E., Kaczmarek-Szewczyk J., Kaczmarzyk M., Kandziara R., Kaniewski C., Karolak-Brandt L., Kasperczyk S., Kasparek-Dyłał E., Kedziara I., Kępa A., Kiciński J., Kielak-Al-Hosam J., Kielczawa Ł., Kilimowicz P., Kitiński K., Kiwka T., Klein U., Klichowicz L., Klimowicz A., Klonowski B., Kmolek B., Kobyłko-Klepcka E., Kocoi A., Kolenda A., Kolek E., Kopeć M., Koper-Kozikowska B., Koralewska J., Korczyńska M., Korzeniewski M. T., Kosk A., Kotarski K., Kowalczyk E., Kowalczyk M., Kowalik I., Kozak-Błazkiewicz B., Kozik M., Kozłowska D., Kozłowska E., Kozłowska M., Kozubski T., Kózka K., Kraśnik L., Kręziak T., Krochmal B., Król B., Król G., Król J., Królikowska T., Kruszecka H., Krygier-Potrykus B., Krystek W., Krzysztoń J., Kubicki T., Kuczmierczyk-El-Hassan A., Kuczyńska-Witek W., Kujda D., Kurowski A., Kurzelewska-Solarz I., Kwaczyńska M., Kwaśniak M., Kwaśniak P., Kwietniewska T., Lebek-Ordon A., Lebedowicz A., Lejkowska-Olszewska L., Lentas M., Lesiewicz-Ksycińska A., Limanowski M., Loniewski S., Łopata J. A., Lubińska B., Łukasik I., Łuźna M., Lysiak M., Lysik B., Machowski Z., Maciaczyk-Kubiak J., Mackiewicz-Zabochnicka G., Magner-Kręziak Z., Majda S., Malinowski P., Mantyka J., Marchlik E., Martyna-Ordyniec G., Marzec J., Marzec M., Matejko-Wałkiewicz R., Mazur M., Michalczak M., Michalska-Zyłka A., Michniewicz M., Mika-Stanisławska D., Mikiciuk E., Mikołajczak T., Milewski J., Miller E., Misiaszek B., Mizik-Lukowska M., Mityńczyk-Pokutyczka E., Mocek M., Moczala M., Morawska-Hermanowicz M., Moryc P., Moskal A., Moskal S., Moździerz A., Moździerz P., Mrozińska M., Mrozowicz K., Mróz G., Munia T., Mura A., Muras-Skudlarska M., Murawska E. Z., Murawski Ł., Murawski R., Musielak R., Nadaj K., Nagarnowicz W., Napierała R., Niedźwiecka M., Niemirski A., Nikiel J., Nosal M., Nowacki W., Nowak J., Nyrka M., Obst A., Ochowicz J., Ogonowska E., Oleszczyk M., Oldakowski A., Ołowniuk-Stefaniak I., Ordowska-Rejman J., Orliński M., Osińska B., Ostańska-Burian A., Paciorkowska A., Paczkowska U., Paluch L., Pałka L.,

Paszko-Wojtkowska J., Paszkowska A., Pawlak-Ganczarska E., Pawlik W., Pawłowska I., Paździora M., Permiakow G., Petlic-Marendziak A., Piasecka T., Piascińska E., Piktel A., Piłarska-Igielska A., Piotrkowska A., Piwowar-Klag K., Planer M., Plewa J., Platkiewicz P., Płonczyńska B., Podgórska A., Polewska M., Porębska B., Porwol P., Potakowska I., Prokop A., Przybylski J., Przybyła M., Psiuk H., Ptak K., Puzoń G., Rabiza N., Rachwałik S., Raczynska E., Raniszewska M., Romanek-Kozik A., Rosa A., Rosa K., Rozewicz A., Rudzka-Kałwak J., Rusak J., Rutkowska D., Rybacki M., Rybińska D., Rycyk-Sadowska A., Rynda L., Rynkiewicz B., Sadowska-Krawczyk B., Sadowska-Zarzycka M., Sarnecka B., Sawalach-Tomanik E., Sidor-Drozd B., Siemieniak-Dębska M., Sieroń A., Siewniak-Zalewska B., Sikora A., Sitarska-Pawlina B., Skorupski J., Skrzyńska-Mansfeld I., Skubisz J., Skwara R., Stodyczka M., Smentek M., Smolińska K., Solarz B., Sosnowska W., Sroka B., Stachura H., Stangrećiak D., Staniak M., Stańczyk Z., Stańczak-Ozga D., Startek E., Stefańczyk M., Stelmach R., Sternadel-Rączka E., Sternik M., Stępień J., Stocka J., Stokowska-Wojda M., Studler-Karpińska M., Suchorokow W., Sufryd W., Supłacz B., Sygacz J., Szczepański Ł., Szkandera J., Szłapa-Zellner J., Szydłarska D., Śliwa T., Śliwka J., Śmiejkowski Ł., Targońska A., Tesarska E., Tobiasz M., Tomaka J., Tomalska-Bywałec K., Tomiak E., Topczewski S., Trawińska A., Treła-Mucha L., Trojanowski D., Trzaskowska M., Trzciska-Larska B., Trznadel-Mozul A., Ulanicka-Liwoch K., Urbanowicz M., Uthke-Kluzek A., Waczyński J., Walczak J., Warsz L., Wasylczuk M., Wąchala-Jędras U., Wąsowicz D., Wczyśla J., Wenda F., Werner-Kubička E., Weryszko E., Węgrzynowska B., Wiaska M., Wiankowski M., Wicherek A., Wieczorek R., Wieniec R., Wieniec-Tatara G., Wierzbicka B., Wierzbicki M., Wilczyńska B., Wilmańska D., Winiarski P., Wiszniewska-Pabiszczak A., Witkowska M. B., Witzling J., Właż A., Wojtkowiak I., Woydyłło J., Woźniak K., Wójciszewski A., Wrona J., Wronska M., Wujkowska H., Wyrąbek J., Wysokiński O., Zakrzewski R., Zaleska-Zatkaik J., Zaleski J., Zalewska-Dybciak M., Zalewska E., Zalewska-Uchimiak B., Zawadzka-Krajewska J., Zawadzki J., Zieliński A., Zubrycka E., Zybort I., Żymek M.

TYPE: Original Research

FUNDING: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The present study was an initiative of the Polish Lipid Association (PoLA) and the College of Family Physician in Poland (CFPIP). The present study was funded by an unrestricted educational grant from Valeant (Warsaw, Poland). Valeant had no role in study design, data analysis, data interpretation, or writing of the report. The present study was also supported by Silesian Analytical Laboratories (SLA), CHDE, BIO-RAD, and Euroimmun. The study was funded by the Medical University of Silesia, grant no. PCN-2-001/N/1/O.

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jacek J. Józwiak and Maciej Banach have received an unrestricted educational grant from Valeant, and has served as a consultant or speaker for Valeant. Paweł Krzemień is employed by Euroimmun Polska Sp. z o.o. (Wrocław, Poland), whose autoantibody reagents were used in the study. Peter E. Penson owns 4 shares in AstraZeneca PLC and has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp, Sanofi. All others authors declare no conflicts of interest concerning the results of this analysis.

CORRESPONDING AUTHOR: Paweł Krzemień, Euroimmun Polska Sp. z o.o., 2a Widna Street, Wrocław 50-543, Poland. Email: p.krziemien@euroimmun.pl

Introduction

Although many autoantibodies are detectable, not all are associated with specific connective tissue diseases, even though some of them are detected in very high titers.^{1,2} In recent years, one of the most commonly and widely described autoantigen of unknown clinical significance is stress oncoprotein lens epithelium-derived growth factor p75 (LEDGF/p75), also known as dense fine speckled 70 kDa (DFS70) autoantigen. The clinical relevance of anti-DFS70 autoantibodies remains unknown and still requires investigation.^{3,4} It is unclear whether anti-DFS70 autoantibodies play a pathogenic or protective role.⁵ Furthermore, the underlying cause of anti-DFS70 formation is not known.

The dense fine nuclear speckled pattern was first described by Ochs et al⁶ and the associated antigen was named DSF70 in 2000.⁷ A year earlier, Toshimichi Shinohara's group, working independently, called it LEDGF/p75, not knowing that it was related to DFS70,⁸ and a few years later the protein and the gene were named PSIP1 (PC4 and SFRS1 Interacting Protein 1).^{9,10} According to the primary studies, DFS70/LEDGF/p75 was thought to be a crucial factor in lens epithelial cell proliferation, but further studies have shown that this protein is a common cell growth promoter or transcription factor that is activated in response to increased stress conditions in the cell

microenvironment.¹¹⁻¹⁴ Examples of such situations include increased oxidative stress induced by the use of cytotoxic drugs that induce oxidative DNA damage or exposure to radiation.¹⁵ The important role of DFS70/LEDGF/p75 as a regulator of gene transcription activated in response to inflammatory stress occurring in autoimmune diseases, cancer, and also in the pathophysiology of acquired immunodeficiency syndrome (AIDS) has also been demonstrated.¹⁵⁻²² Expression of DFS70/LEDGF/p75 protein therefore increases the chance of cell survival under various stress conditions in both diseased and healthy individuals.

Reactive oxygen species (ROS) can induce posttranslational modifications in certain proteins that can be recognized by the immune system as neopeptides that are source of autoantibody formation.²³⁻²⁶ As suggested by Ortiz-Hernandez et al²⁷ the autoantibody response to DFS70/LEDGF/p75 could be considered as a possible marker of increased oxidative stress which, in a pro-inflammatory microenvironment, leads, on the one hand, to increased expression of this protein and on the other, may cause its post-translational modifications. Moreover, Wu et al observed that during enhanced oxidative stress, DFS70/LEDGF/p75 undergoes thioredoxin1 (Trx1) mediated post-translational modifications involving cysteine reduction to maintain its stress-modulating function. These findings clearly




Figure 1. Research procedural stages.

show the potential for the protein to be modified.²⁸ Unfortunately, there is still no evidence that such stress-associated modifications increase the immunogenicity of this protein.

In this study, we evaluated the coexistence of anti-DFS70 antibodies with selected oxidative stress markers and their relationship with sociodemographic factors. We evaluated whether the anti-DFS70 could be considered to be an indirect marker of oxidative stress. In addition, we estimated the prevalence of anti-DFS70 antibodies in the Polish population.

Materials and Methods

A simplified scheme of the study is shown in Figure 1.

Design

A nationwide observational, cross-sectional study was carried out in Poland in the fourth quarter of 2015 and the first and second quarters of 2016.

Sampling

This study is part of a large research program, “Nationwide study of cardiovascular health in primary care in Poland—LIPIDOGRAM2015 and LIPIDOGEN2015,” the design and rationale of which have been described in detail previously by Józwiak et al.²⁹ Briefly, the recruitment was carried out by

438 primary care physicians in 16 major administrative regions of Poland. Physicians/investigators were randomly selected from the Medical Data Management database. The expected number of patients recruited for LIPIDOGRAM2015 study (consecutive sample) was 13 000 to 14 000 with 13% to 15% (1700–2000) enrolled to the LIPIDOGEN2015 sub-study (random sample). The program included only adult patients over 18 years old. Each patient had to complete a questionnaire concerning medical and family history, concomitant diseases, and pharmacotherapy. The following criteria were used in the physical activity question: regular physical effort—increased activity of the musculoskeletal system, regularly for 2 to 2.5 hours/week, defined as exercising, walking, running, swimming, playing team games, dancing, and doing housework or household chores; or no regular physical activity—people who do not meet the criteria of regular physical activity; or others who did not provide detailed information on the level of their physical activity. In the question concerning the use of diet (hypolipemic, hypoglycemic, hypotensive) the following criteria were used: use of an appropriate diet—regular consumption of varied low cholesterol foods, moderate consumption of medium cholesterol foods, reduced consumption of saturated fats—in favor of monounsaturated and polyunsaturated fats, reduced consumption of carbohydrates and sweetened drinks, reduced consumption of table salt, increased consumption of

fish, increased consumption of fruit and vegetables and fiber-rich foods or no use of an appropriate diet—those not meeting the criteria for following an appropriate diet. Anthropometric measurements (height, body weight, waist circumference, and hip circumference) were performed at the doctor's office. In all enrolled patients, serum samples were obtained after ≥ 12 hours of fasting. On the same day, measurements of blood pressure, heart rate, and fasting glucose were obtained in addition to lipid profiles. For the LIPIDOGEN2015 sub-study, saliva samples for DNA isolation and blood samples were collected to measure glycated hemoglobin, oxidative stress parameters, autoantibody levels, and inflammatory cytokine and apolipoprotein profiles.

For this study, we used 1731 serum samples from the above-mentioned LIPIDOGEN2015 sub-study. The tested group included 1043 women and 688 men. The blood samples were transferred in cooled containers (-20°C) to a central laboratory (Silesian Analytical Laboratories—SLA in Katowice, Poland) for biochemical analyses and then to the autoimmune laboratory (Euroimmun Poland Ltd. Customer Training Laboratory in Wrocław, Poland) for Anti-nuclear Antibodies (ANA) determination.

Laboratory analyses

Measurements of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (direct immunological measurement) were performed and carried out using the same methodology and the same Siemens Advia 1800 analyser and Siemens reagents (Munich, Germany), within 12 hours of obtaining the blood sample. Fasting glucose levels were measured using Bionime glucometers (Taichung City, Taiwan) and Rightest strip tests (Taichung City, Taiwan).

For the evaluation of the intensity of oxidative stress, the indices of free-radical damage to lipids and proteins, enzymatic and non-enzymatic antioxidant system parameters in serum and erythrocytes were measured. In serum, indices of free-radical damage to lipids and proteins include: total oxidant status (TOS),³⁰ lipid hydroperoxides (LPH),³¹ lipofuscin (LPS),³² and malondialdehyde (MDA)³³ concentration. The activity of superoxide dismutase (SOD)³⁴ was determined in serum. In addition, parameters of non-enzymatic antioxidant systems, such as total antioxidant status (TAS)³⁵ and uric acid (UA) were also measured. The oxidative stress index (OSI) was calculated using the TOS/TAS formula. In erythrocytes, the indices of free-radical damage to lipids and proteins, such as LPS and MDA, were determined as was the activity of SOD.³⁴

In the second phase, ANA were detected using an indirect immunofluorescence assay (IFA) in human laryngeal carcinoma cells (HEp-2) with commercially available Euroimmun Medizinische Labordiagnostika AG (Lübeck, Germany) test kits Mosaic Basic Profile 3 (catalog number FC 1800-2010-3). Sample incubation was carried out manually, according to the

manufacturers' instructions, except that 998 samples were diluted with a threshold cut-off 1:160 as recommended by the current guidelines³⁶ and 733 patient samples were diluted with a threshold cut-off 1:100 as recommended by the test kit manufacturer's instruction. The samples were divided into 2 groups randomly. The results were evaluated on a EUROstar III fluorescence microscope (CarlZeiss Oberkochen, Germany). The test result included a qualitative assessment of the presence of ANA, estimation of antibody titer, and determination of the characteristic pattern according to the International Consensus on ANA Patterns (ICAP) nomenclature.³⁷ Results of IFA were collected and stored as digital images.

In the third phase, the concentration of anti-DFS70 antibodies was determined using ELISA. We used commercially available Euroimmun Medizinische Labordiagnostika AG (Lübeck, Germany) test kits (catalog number EA 159z-9601 G). Incubation was performed automatically with Euroimmun Analyzer I (Lübeck, Germany) according to the instructions included with the test kit. In this phase, we tested 357 preselected samples, of which 129 were samples with AC-2 dense fine speckled pattern (usually associated with the presence of anti-DFS70 antibodies) positive in the screening. The control group consisted of a random selection of 228 samples, out of which 84 were ANA positive in a screening test but with another type of pattern, and 144 were ANA negative samples. The ELISA results were expressed using the semi-quantitative Ratio index, which is the ratio of sample extinction to cut-off calibrator extinction. According to the ELISA test manual, Ratio index ≥ 1.0 was considered positive.

Statistical analysis

Statistical analyses were carried out were performed using Statistica 13.3 (StatSoft, Tulsa, USA). Data are expressed as mean \pm SD (for normal distribution) and median (nonparametric distribution) for continuous variables, and as a percentage for categorical variables. Univariate comparison of markers related to autoimmune diseases according to clinical variables was performed using the *U*-Mann-Whitney method for nonparametric variables or χ^2 test/Fisher exact test where appropriate. A 2-sided $P < .05$ was considered to indicate significance. Additionally, regression analysis was performed (R —multiple correlation coefficient, R^2 coefficient of determination, β^* —regression standardized coefficient) and Pearson's correlation were calculated.


Results

The study included 357 patients attending primary health care practices (251 women and 106 men). Two hundred and twenty-six participants were diagnosed with a range of cardiovascular and renal disorders (eg, hypertension, coronary artery disease, dyslipidemia, diabetes, atrial fibrillation, kidney disease, or stroke), and 131 participants were apparently healthy individuals. The mean age of participants was 53 ± 12 years. The body

Table 1. Characteristics of the population.

	ALL (N=357)		MALE (N=106)		FEMALE (N=251)	
	MEAN	SD	MEAN	SD	MEAN	SD
Age (years)	53.0	12.5	53.7	12.4	52.7	12.6
Height (cm)	166.8	8.53	176.0	6.45	162.9	5.94
Weight (kg)	78.6	15.9	90.2	13.8	73.7	14.1
BMI (kg/cm ²)	28.2	4.90	29.0	3.71	27.8	5.28
Waist circumference (cm)	93.2	13.4	100.9	9.46	90.0	13.5
Hips circumference (cm)	105.1	10.6	104.1	8.64	105.5	11.3
WHR	0.89	0.09	0.97	0.07	0.85	0.07

Abbreviations: BMI, body mass index; WHR, waist-hip ratio.

**Figure 2.** ANA AC-2 pattern distribution depending on the titer.

mass index (BMI) indicated that the participants were on average slightly overweight,³⁸ and the average waist-hip ratio (WHR) was above the normal range for both men and women.³⁹ No difference in age between men and woman ($P = .483$) was found (Table 1).

In the initial group of 1731 samples, from which we selected samples for the main study group, we found ANA in 15.02% (260/1731). The most frequent pattern was AC-2 dense fine speckled, detected in 50% (130/260) of all ANA positive samples, which accounted for 7.51% of all samples tested. One sample was AC-2 positive, but sufficient material was not available for further ELISA testing.

In our main study group, consisting of preselected 357 samples, 129 were determined to be AC-2 positive. This type of pattern is most often associated with anti-DFS70 antibodies.^{3,36} The majority of them are samples in low titer (Figure 2). The presence of anti-DFS70 antibodies was confirmed by monospecific ELISA test in 21.29% (76/357) of samples. Extrapolation of these data allows us to estimate that the prevalence of anti-DFS70 in the Polish population is 4.39% (76/1731). Table 2 summarizes the presence of anti-DFS70 antibodies categorized by sample type. In a group of mixed patterns, there were 2 samples with additional pattern AC-21 and 1 sample each with patterns AC9/10, AC-27, and AC 25/26.

In 6 of the samples classified as ANA negative, anti-DFS70 antibodies were found. In 4 samples, the Ratio index was low (1.08-1.56). In 1 sample, the Ratio index was raised (2.37) and was very high (6.47) in another. Table 3 presents the distribution of anti-DFS70 antibodies in ANA positive samples by staining pattern. The AC-2 pattern occurred most frequently. Anti-DFS70 antibodies are confirmed in samples characterized by AC-1, AC4/AC5, and AC-27 patterns.

Table 4 presents the distribution of anti-DFS70 antibodies according to the gender and age of participants. Anti-DFS70 are more prevalent in young people ($P = .008$), but when analyzed by sex, this was only the case for women ($P = .003$).

When comparing participants with and without cardiovascular and renal disorders, anti-DFS70 antibodies were present more commonly in those free of disease (27.5%, 36/131, $P = .03$). These antibodies were also observed less frequently in patients with arterial hypertension ($P = .023$). In our cohort, smokers seem to produce fewer antibodies, whether they still smoke ($P = .002$) or have done so in the past ($P = .006$). Comprehensive results of analysis of the prevalence of anti-DFS70 antibodies and various lifestyle factors, cardiovascular and renal diseases are shown in Table 5.

The relationship between the presence of anti-DFS70 antibodies and individual markers of oxidative stress is summarized in Table 6. We observed a 23% lower concentration of lipid hydroperoxides (LPH) ($P = .038$) and 11% lower concentration of uric acid (UA) ($P = .005$). Total oxidant status (TOS) was 20% lower ($P = .014$) than in patients without anti-DFS70 antibodies. Additionally, these results were accompanied by slightly higher (up to 5%) activity of superoxide dismutase (SOD) ($P = .037$) in red blood cells. Other oxidative stress markers did not differ significantly between the compared groups.

We also evaluated whether or not whether associations exist between higher concentrations of anti-DFS70 antibodies and individual oxidative stress markers. For this purpose, we arbitrarily divided the anti-DFS70 positive samples into 2 groups

Table 2. Anti-DFS70 antibodies distribution in tested group.

TESTED GROUP (N = 357)	DFS70 POSITIVE		DFS70 NEGATIVE	
	N = 76		N = 281	
	N (%)		N (%)	
AC-2—dense fine speckled	65	(18.21)	59	(16.53)
Mixed pattern (AC-2 + other ANA ^a)	1	(0.28)	4	(1.12)
Other ANA positive	4	(1.10)	80	(22.41)
ANA negative	6	(1.70)	138	(38.66)

Abbreviations: AC, anti-cell; ANA, anti-nuclear antibody; DFS70, dense fine speckled.

^aTwo samples additionally showed pattern AC-21 and 3 more samples additionally showed patterns AC9/10, AC-27, and AC 25/26, 1 additional type in each of the 3 samples.

Table 3. Anti-DFS70 antibody distribution depending on the ANA positive pattern.

TYPE OF PATTERN	ANTI-DFS70 (+)		ANTI-DFS70 (-)		P-VALUE
	POSITIVE	NEGATIVE	POSITIVE	NEGATIVE	
AC-1—Homogenous	2	74	8	273	.771
AC-2—Dense fine speckled	66	10	63	218	<.001
AC-3—Centromere	0	76	3	278	.844
AC4/AC5—Fine/large/coarse speckled	2	74	36	245	.019
AC6/AC7—Multiple/few nuclear dots	0	76	2	279	.879
AC-8—Homogenous nucleolar	0	76	1	280	.482
AC-9/AC-10—Clumpy/punctate nucleolar	0	76	28	253	.004
AC-15—Fibrillar linear	0	76	2	279	.879
AC-16—Fibrillar filamentous	0	76	1	280	.482
AC-21—Reticular/AMA	0	76	9	272	.036
AC-23—Rods and rings	0	76	1	280	.482
AC-25/AC-26—Spindle fibers/NuMA-like	0	76	3	278	.844
AC-27—Intercellular bridge	1	75	1	280	.879
AC-28—Mitotic chromosomal	0	76	1	280	.482

Abbreviations: AC, anti-cell; AMA, antimitochondrial antibodies; ANA, anti-nuclear antibody; NuMA, nuclear mitotic apparatus.

of low (1-4) or high (>4) ratio index. The results are presented in the Table 7. Statistically significant differences were observed for samples with high anti-DFS70 titer. Lower TOS ($P = .001$), LPH ($P = .002$), UA ($P = .003$) LPS in serum ($P = .001$), LDL ($P = .056$) tendency and higher SOD activity ($P = .045$) were reported in high ratio index of anti-DFS70 positive patients compared to the anti-DFS70 negative patients. Lower MDA ($P = .024$) in serum were reported in ratio index 1 to 4 of anti-DFS70 positive patients compared to the anti-DFS70 negative patients.

The Pearson correlation showed statistically significant but weak, negative correlations between anti-DFS70 prevalence

and the levels of LDL ($P = .063$), LPH ($P = .003$), UA ($P = .004$), and TOS ($P = .006$). In addition, there was a weak positive correlation between anti-DFS70 prevalence and SOD activity ($P = .028$) (Table 8). Regression analysis showed that the parameters which influence the occurrence of anti-DFS70 antibodies included: concentration of lipid hydroperoxides (for LPH $\beta^* = -.16$), and concentration of uric acid (for UA $\beta^* = -.15$). The value of regression analysis was $R = .22$, $R^2 = .05$, $P < .001$.

We also made an extended analysis of the surprising results concerning the lack of association of cigarette smoking, with the presence of anti-DFS70 antibodies, as smoking is known

Table 4. Characteristics of the population depending on age in the occurrence of anti-DFS70 antibodies.

AGE	ALL (N=357)			MALE (N=106)			FEMALE (N=251)			P-VALUE (MALE VS FEMALE)
	N	POSITIVE DFS70	POSITIVE DFS70 (%)	N	POSITIVE DFS70	POSITIVE DFS70 (%)	N	POSITIVE DFS70	POSITIVE DFS70 (%)	
<30	14	6	42.86	3	0	0.00	11	6	54.55	.989
≤30-40	48	16	33.33	11	5	45.45	37	11	29.73	.339
≤40-50	71	16	22.54	28	6	21.43	43	10	23.26	.090
≤50-60	106	24	22.64	26	6	23.08	80	18	22.50	.713
≤60-70	93	9	9.68	29	5	17.24	64	4	6.25	.073
≥70	25	5	20.00	9	1	11.11	16	4	25.00	.346
P-value (vs age) ^a	.008			.363			.003			

Abbreviation: DFS70, dense fine speckled.

^aComparison male versus female dependently of age.**Table 5.** The occurrence of anti-DFS70 antibodies depending on lifestyle and civilization diseases.

TESTED GROUP (N=357)	ANTI-DFS70 NEGATIVE	ANTI-DFS70 POSITIVE	P-VALUE
	(N=281)	(N=76)	
	N (%)	N (%)	
Sex (% of men)	83 (29.5)	23 (30.3)	.903
Physical activity	116 (41.3)	35 (46.1)	.456
Dietary habits	172 (61.2)	52 (68.4)	.250
Tobacco smoking (current or in the past)	130 (46.3)	22 (28.9)	.006
Current tobacco smoking	45 (16.0)	2 (2.6)	.002
Alcohol consumption	194 (69.0)	45 (59.2)	.116
Chronic kidney disease	9 (3.2)	0 (0.0)	.115
Coronary artery disease	31 (11.0)	7 (9.2)	.649
Myocardial infarction	16 (5.7)	1 (1.3)	.112
Ischemic stroke	7 (2.5)	0 (0.0)	.166
Hemorrhagic stroke	1 (0.4)	0 (0.0)	.604
Atrial fibrillation	12 (4.3)	2 (2.6)	.515
Dyslipidemia	144 (51.2)	34 (44.7)	.315
Family hypercholesterolemia	10 (3.6)	1 (1.3)	.317
Diabetes mellitus	56 (19.9)	14 (18.4)	.770
Arterial hypertension	141 (50.2)	27 (35.5)	.023
Healthy individuals	95 (33.8)	36 (47.4)	.030

to increase the intensity of oxidative stress. The results are presented in Table 9. Anti-DFS70 positive individuals show a significant decrease in oxidative stress intensity, regardless of whether they are cigarette smokers or not. In anti-DFS70

positive non-smokers we observed a statistically significant 18% decrease in TOS ($P = .051$). Anti-DFS70 positive smokers had 28% lower LPH levels ($P = .032$), 17% lower UA levels ($P = .017$), and 12% higher SOD activity ($P = .002$). The gender

Table 6. The oxidative stress markers depending on occurrence of anti-DFS70 antibodies.

TESTED GROUP (N = 357)	ANTI-DFS70 NEGATIVE (N = 281)		ANTI-DFS70 POSITIVE (N = 76)		% CHANGE	P-VALUE
	MEAN	SD	MEAN	SD		
TC (mg/dl)	212.4	49.4	205.6	47.1	-3	.279
HDL-C (mg/dl)	54.2	15.4	55.7	18.6	3	.467
TG (mg/dl)	159.1	127.5	153.7	136.8	-3	.751
LDL-C (mg/dl)	137.6	44.4	130.2	42.4	-5	.192
Non-HDL (mg/dl)	158.2	48.4	149.9	46.7	-5	.179
TAS (mmol/l)	1.05	0.26	1.05	0.27	0	.939
TOS (μ mol/l)	7.41	6.44	5.93	3.96	-20	.014
LPH (μ mol/l)	4.15	3.82	3.19	2.46	-23	.038
UA (μ mol/l)	376	108	336	94	-11	.005
MDA (μ mol/l)	3.11	1.33	2.89	1.09	-7	.201
MDA nmol/gHb	297	108.2	290	95.68	-2	.655
LPS RF (serum)	362	174	338	140	-7	.266
LPS RF/gHb	609	236	583	245	-4	.404
SOD NU/ml (serum)	20.01	2.60	19.55	3.03	-2	.189
SOD NU/mgHb	183	28.63	191	37.26	5	.037

Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LPH, lipid hydroperoxides; LPS, lipofuscin; MDA, malondialdehyde; Non-HDL, non-high density lipoprotein cholesterol; SOD NU, superoxide dismutase nitrite units; TAS, total antioxidant status; TC, total cholesterol; TG, triglycerides; TOS, total oxidant status; UA, uric acid.

of smokers and non-smokers was not associated with the presence of anti-DFS70 antibodies.

Discussion

In this study, our principal finding was that reduced levels of oxidative stress were observed in anti-DFS70 positive samples, especially in samples with a high antibody titer. These findings suggest that anti-DFS70 antibodies can be considered as an indirect marker of antioxidant response. Secondly, the prevalence of anti-DFS70 in the Polish population is low and can be estimated at 4.39%.

The AC-2 pattern, defined by a dense and heterogeneous speckled staining in the nucleoplasm of interphase HEp-2 cells (sparing the nucleoli) and the metaphase chromosomal plate,³⁶ was the most commonly recognized pattern type in our study. The AC-2 pattern is related to anti-DFS70 antibodies, so we expected to confirm the presence of these antibodies, especially in these samples, but the percentage of confirmations was surprisingly low, at only 51.16% (66/129). Other investigators have also reported wide variations in concordance between suspected IFA and confirmation by DFS70 specific solid-phase assays.^{17,40-45} For example, Carter et al¹⁷ and Carbone et al⁴⁴ reported slightly lower percentages of confirmation in their studies—41% and 45.8%, respectively. There are several hypotheses that may explain these discrepancies. First, the

experience of laboratory staff is of great importance because IFA is a highly subjective method. This is best seen in samples with a low autoantibody titer. More than half of the samples scored as AC-2 positive were very low titer samples, 43.41% (56/129) with a titer of 1:100 and 28.68% (37/129) with a titer of 1:160 (Figure 2). Furthermore, for such samples, the level of anti-DFS70 antibodies in the monospecific test may not be higher than the cut-off value (in our case Ratio index ≥ 1). Unfortunately, there is no international standard for anti-DFS70 antibodies, so each test manufacturer must set an appropriate cut-off value for its own monospecific test. This may result in discrepancies in the interpretation of results of tests offered by different manufacturers. Additionally, we cannot exclude the possibility of some misidentification of the AC-2 pattern. It is possible that the antibodies that give an AC-2 pattern staining are in fact a rather heterogeneous group. It has been proposed recently to define a new separate pattern of staining called “non-DFS” or “pseudo-DFS,”⁴⁶ comprising nuclear speckled patterns with clear staining of the metaphase plate, but without the typical features of the AC-2 pattern.⁴⁷ The new pseudo-DFS pattern may be caused by autoantibodies other than anti-DFS70 or recognizing distinct DFS70/LEDGF/p75 protein epitopes¹⁷ which may also explain the negative results of anti-DFS monospecific tests.^{46,47} A further problem is that patterns similar to AC-2 or overlapping

Table 7. The oxidative stress markers depending on anti-DFS70 antibodies concentration.

TESTED GROUP (N=357)	ANTI-DFS70 NEGATIVE		ANTI-DFS70 POSITIVE					
	RATIO INDEX 0-1 (N=281)		RATIO INDEX 1-4 (N=35)		RATIO INDEX >4 (N=41)			
	MEAN	SD	MEAN	SD	P-VALUE	MEAN	SD	P-VALUE
TC (mg/dl)	212.4	49.4	208.4	42.33	.647	203.1	51.14	.264
HDL (mg/dl)	54.2	15.4	54.85	17.58	.816	56.44	19.55	.399
TG (mg/dl)	159.1	127.5	142.0	91.68	.443	163.8	166.6	.832
LDL (mg/dl)	137.6	44.4	138.0	41.13	.966	123.6	42.82	.056
Non-HDL (mg/dl)	158.2	48.4	153.6	39.83	.585	146.7	52.07	.159
TAS (mmol/l)	1.05	0.26	1.05	0.31	.888	1.04	0.23	.806
TOS (μmol/l)	7.41	6.44	6.73	4.61	.544	5.25	3.20	.001
LPH (μmol/l)	4.15	3.82	3.57	2.81	.387	2.86	2.10	.002
UA (μmol/l)	376	108	354.1	91.53	.261	321.9	94.65	.003
MDA (μmol/l)	3.11	1.33	2.58	1.02	.024	3.16	1.08	.797
MDA nmol/gHb	297	108.2	292.4	99.68	.829	288.8	93.34	.662
LPS RF (serum)	362	174	380.3	172.9	.550	301.0	91.93	.001
LPS RF/gHb	609	236	582.6	209.7	.535	583.1	274.5	.528
SOD NU/ml (serum)	20.01	2.60	19.96	2.97	.917	19.21	3.07	.287
SOD NU/mgHb	183	28.63	188.9	31.58	.251	193.2	41.80	.045

Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LPH, lipid hydroperoxides; LPS, lipofuscin; MDA, malondialdehyde; Non-HDL, non-high density lipoprotein cholesterol; SOD NU, superoxide dismutase nitrite units; TAS, total antioxidant status; TC, total cholesterol; TG, triglycerides; TOS, total oxidant status; UA, uric acid.

Table 8. Pearson's correlation between anti-DFS70 and selected parameters.

PARAMETERS	R	P-VALUE
LDL-C (mg/dl)	-.10	.063
TOS (μmol/l)	-.15	.006
LPH (μmol/l)	-.16	.003
UA (μmol/l)	-.16	.004
SOD NU/mgHb	.12	.028

Abbreviations: LDL-C, low-density lipoprotein cholesterol; LPH, lipid hydroperoxides; SOD NU, superoxide dismutase nitrite units; TOS, Total oxidant status; UA, uric acid.

staining that can obscure the presence of the AC-2. In our study, antibodies-DFS70 were detected in 2 samples evaluated as AC-1 (overlap) and in 2 samples evaluated as AC4/AC5 (can be similar), that fulfill these conditions. Moreover, in samples with the AC4/AC5 pattern, the likely occurrence of anti-DFS70 antibodies was statistically significantly higher ($P = .019$). We also observed 6 DFS70 positive samples in the ANA negative control group. Four of these were samples that were close to the cut-off, which confirms the possibility of

discrepancies between IFA and monospecific assays for samples with low titers.

Severe systemic oxidative stress is considered to be one of the factors that may contribute to the formation of autoantibodies, including anti-DFS70.^{23,48,49} Theoretically, the chain of events could be as follows: If conditions of oxidative stress prevail, antioxidative mechanisms are activated, including increased production of DFS70/LEDGF/p75, as demonstrated by Singh et al.⁸ It is possible that under these conditions, the DFS70/LEDGF/p75 may undergo some posttranslational modifications induced by ROS, resulting in the formation of neoepitopes that may initiate an immune response and antibody production which can then cross-react and recognize native DFS70/LEDGF/p75 secondary to molecular mimicry. In our study, statistically significant changes in some oxidative stress markers were observed in patients with anti-DFS70 antibodies, but the observations were different from those previously assumed. In fact, lower concentrations of some markers were observed, accompanied by slightly higher SOD activity (Table 6).

These results indicate a generally decreased level of oxidative stress in subjects with anti-DFS70 antibodies. Moreover, the results presented in Table 7 show that this relationship is

Table 9. The oxidative stress markers and sex depending on occurrence of anti-DFS70 antibodies in relation to smoking (smokers—tobacco smoking current or in the past and non-smokers).

		ANTI-DFS70 NEGATIVE			ANTI-DFS70 POSITIVE			% CHANGE	P-VALUE
		N	MEAN	SD	N	MEAN	SD		
TOS (μmol/l)	All	281	7.41	6.44	76	5.93	3.96	-20%	.014
	Non-smokers	151	7.29	6.90	54	5.94	3.82	-18%	.051
	Smokers	130	7.55	5.88	22	5.90	4.37	-22%	.131
LPH (μmol/l)	All	281	4.15	3.82	76	3.19	2.46	-23%	.038
	Non-smokers	151	4.07	4.07	54	3.25	2.62	-20%	.094
	Smokers	130	4.25	3.51	22	3.05	2.09	-28%	.032
UA (μmol/l)	All	281	376	108	76	336	94	-11%	.005
	Non-smokers	151	372	102	54	345	88	-7%	.069
	Smokers	130	381	115	22	315	107	-17%	.017
SOD NU/mgHb	All	281	183	28.63	76	191	37.26	5%	.037
	Non-smokers	151	184	29.72	54	186	33.56	1%	.668
	Smokers	130	182	27.39	22	204	43.33	12%	.002
		N (%)			N (%)			P-VALUE	
Sex (% of men)	All	83 (29.5)			23 (30.3)			.903	
	Non-smokers	27 (17.9)			14 (25.9)			.206	
	Smokers	56 (43.1)			9 (40.9)			.850	

Abbreviations: LPH, lipid hydroperoxides; SOD NU, superoxide dismutase nitrite units; TOS, total oxidant status; UA, uric acid.

particularly relevant in patients with a high titer of anti-DFS70 antibodies and was not observed in patients with a lower titer of antibodies (except for a slightly lower MDA concentration). It is also appropriate to quote here the hypothesis presented by Infantino et al⁵ which proposed that autoantibodies targeting the DFS70/LEDGF/p75 protein may be involved in the removal of protein cleavage fragments from debris generated during cell death and tissue damage. It is assumed that in such a case, the anti-DFS70 antibodies could be produced as a result of increased oxidative stress associated with the collapse of the anti-oxidative systems, leading to the death of cells either through apoptosis or necrosis.⁵⁰⁻⁵² Perhaps the overexpression of the PSIP1 gene, on the one hand, results in lowering the level of oxidative stress, increasing the likelihood that the cell will survive, and on the other hand, the excess protein needs to be removed—this can be supported by immune mechanisms associated with autoantibody production. As Singh et al⁸ have shown in the abovementioned publication, under in vitro conditions of oxidative stress, the DFS70/LEDGF/p75 protein is released into the culture medium. If the same process also takes place in vivo, the DFS70/LEDGF/p75 protein could more easily become an autoantigen for the immune system that would not interfere with its primary protective functions. Posttranslational modifications, as a result of ROS cannot be excluded either.

The hypothesis put forward by Ortiz-Hernandez et al²⁷ is supported by our results. It presupposes that the autoantibody response to DFS70/LEDGF/p75 might be a “sensor” of increased oxidative stress.²⁷ Our results confirm that high titers of anti-DFS70 antibodies may be regarded as a “sensor” of the body’s response to oxidative stress. Hence, the antibodies are associated with reduced levels of oxidative stress markers, and may indicate elevated oxidative stress in the recent past. Moreover, the surprising results presented in Table 5, demonstrating less frequent occurrence of anti-DFS70 antibodies in cigarette smokers, led to the conclusion that smoking in itself does not increase the risk of anti-DFS70 antibodies, but smokers in whom anti-DFS70 antibodies are present appear to cope much better with oxidative stress induced by smoking than anti-DFS70 negative individuals (Table 9). This observation supports the conclusion that the very presence of anti-DFS70 antibodies could be an indicator of efficient antioxidant systems within the body. These antibodies were consistently observed in healthy rather than diseased individuals.

The observation of low TOS level in patients with a high titer of anti-DFS70 may indicate that the presence of anti-DFS70 antibodies does not initiate the advanced immune response process usually associated with increased oxidative stress. Furthermore,

anti-DFS70 is unlikely to inhibit the function of DFS70/LEDGF/p75, otherwise, in both cases, we would expect to observe increased oxidative stress. However, according to Ochs et al¹² a neutral or even protective effect of these antibodies could be context-dependent, raising the possibility that they may also behave as pathogenic antibodies under certain conditions. This conclusion is supported by early studies, which showed that anti-DFS70 antibodies are cytotoxic to cultured lens and lens epithelial cells, possibly by blocking extracellularly released DFS70/LEDGF/p75 from reintroduction into the cells, thus preventing their protective action against stressors.^{53,54} Alternatively, the expression of the PSIP1 gene or its receptor protein may decrease with age,⁸ with the same adverse effects on oxidative stress levels and possibly with a decrease in anti-DFS70 antibodies. This would also explain why anti-DFS70 antibodies are rarely detected in elderly people who are often observed to have impaired antioxidant mechanisms.⁸

The possibility of a false correlation between the 2 phenomena cannot be excluded, owing to the fact that since DFS70 antibodies are detected more frequently in the population of young and healthy people (as our research has also shown), it should be a natural consequence that they are correlated with lower levels of oxidative stress markers.

Conclusions

In samples positive for the anti-DFS70 antibody, a decreased level of oxidative stress was observed, especially in the case of samples with a high antibody titer. Based on the observed associations, we still cannot be sure whether oxidative stress can directly contribute to the formation of anti-DFS70 autoantibodies, but the mere presence of anti-DFS70 antibodies is correlated with low levels of oxidative stress, so anti-DFS70 antibodies may be considered an indirect “sensor” or marker of the body’s antioxidant response. Further temporal studies are needed to determine whether anti-DFS70 antibodies arise as a consequence of oxidative stress.

Acknowledgements

We would like to thank all volunteer LIPIDOGRAM2015 investigators, all staff volunteers and all participants. The list of the LIPIDOGRAM 2015 investigators is in the article.**

Author Contributions

Paweł Krzemień: Conceptualization, Methodology, Investigation, Writing—Original Draft. Sławomir Kasperczyk: Conceptualization, Methodology, Formal analysis, Writing—Review and Editing. Maciej Banach: Conceptualization, Methodology, Project administration, Writing—Review & Editing. Aleksandra Kasperczyk, Michał Dobrakowski, Tomasz Tomasik, Adam Windak, Mirosław Mastej, Alberico Catapano, Kausik K Ray, Dimitri P Mikhailidis, Peter P Toth, George Howard, Greory YH Lip, Maciej Tomaszewski, Fadi J Charchar, Naveed Sattar, Bryan Williams, Thomas M MacDonald and Peter E Penson: Writing—Review and Editing. Jacek JJóźwiak: Conceptualization,

Methodology, Investigation, Supervision, Project administration, Writing—Review and Editing. All authors revised the article critically for important intellectual content. All authors gave final approval of the work have participated sufficiently in the work and take public responsibility for appropriate portions of the content.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the Bioethical Committee of the Chamber of Physicians (No.K.B.Cz.-0018/2015).

Informed Consent

Informed consent was obtained from all individuals included in this study.

REFERENCES

- Grygiel-Górniak B, Rogacka N, Puszczewicz M. Antinuclear antibodies in healthy people and non-rheumatic diseases – diagnostic and clinical implications. *Reumatologia*. 2018;56:243-248.
- Rowley M, Whittingham S. The role of pathogenic autoantibodies in autoimmunity. *Antibodies*. 2015;4:314-353.
- Conrad K, Röber N, Andrade LE, Mahler M. The clinical relevance of anti-DFS70 autoantibodies. *Clin Rev Allergy Immunol*. 2017;52:202-216.
- Mahler M, Andrade LE, Casiano CA, Malyavantham K, Fritzlner MJ. Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. *Expert Rev Clin Immunol*. 2019;15:241-250.
- Infantino M, Carbone T, Manfredi M, et al. Are anti-DFS70 autoantibodies protective? *Isr Med Assoc J*. 2019;21(8):509-511. <http://www.ncbi.nlm.nih.gov/pubmed/31474007>
- Ochs RL, Stein Tw Jr, Peebles CL, Gittes RF, Tan EM. Autoantibodies in interstitial cystitis. *Urol J*. 1994;151:587-592.
- Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. *J Allergy Clin Immunol*. 2000;105:1211-1220.
- Singh DP, Ohguro N, Chylack LT, Shinohara T. Lens epithelium-derived growth factor: increased resistance to thermal and oxidative stresses. *Invest Ophthalmol Vis Sci*. 1999;40(7):1444-1451. <http://www.ncbi.nlm.nih.gov/pubmed/10359326>
- Singh DP, Kimura A, Chylack LT Jr, Shinohara T. Lens epithelium-derived growth factor (LEDGF/p75) and p52 are derived from a single gene by alternative splicing. *Gene*. 2000;242:265-273.
- Sutherland HG, Newton K, Brownstein DG, Holmes MC, Kress C, Semple CA, Bickmore WA. Disruption of *Ledgf/Psip1* results in perinatal mortality and homeotic skeletal transformations. *Mol Cell Biol*. 2006;26:7201-7210.
- Basu A, Sanchez TW, Casiano CA. DFS70/LEDGFp75: an enigmatic autoantigen at the interface between autoimmunity, AIDS, and cancer. *Front Immunol*. 2015;6:116.
- Ochs RL, Mahler M, Basu A, et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. *Clin Exp Med*. 2016;16:273-293.
- Daugaard M, Baude A, Fugger K, et al. LEDGF (p75) promotes DNA-end resection and homologous recombination. *Nat Struct Mol Biol*. 2012;19:803-810.
- Basu A, Cajigas-Du Ross CK, Rios-Colon L, et al. LEDGF/p75 overexpression attenuates oxidative stress-induced necrosis and upregulates the oxidoreductase ERP57/PDIA3/GRP58 in prostate cancer. *PLoS One*. 2016;11:e0146549.
- Rios-Colón L, Cajigas-Du Ross CK, Basu A, et al. Targeting the stress oncogene LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes. *Oncotarget*. 2017;8:24915-24931.

16. Ge H, Si Y, Roeder RG. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. *EMBO J*. 1998;17:6723-6729.
17. Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE. Recognition and relevance of anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. *Front Med*. 2018;5:1-9.
18. Daugaard M, Kirkegaard-Sørensen T, Ostenfeld MS, et al. Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer. *Cancer Res*. 2007;67:2559-2567.
19. Mahroum N, Perez D, Shovman O, et al. Anti-DFS70 among HIV-positive individuals – a prospective study. *Best Pract Res Clin Rheumatol*. 2018;32:605-609.
20. Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? *Arthritis Rheum*. 2004;50:684-688.
21. Kannan S, Daniels T, Casiano CA. LEDGF/p75: a novel nuclear autoantigen at the crossroads of cell survival and apoptosis. *Autoimmun Rev*. 2003;2:290-297. doi:10.1016/S1568-9972(03)00063-6
22. Shinohara T, Singh DP, Fatma N. LEDGF, a survival factor, activates stress-related genes. *Prog Retin Eye Res*. 2002;21:341-358. doi:10.1016/S1350-9462(02)00007-1
23. Smallwood MJ, Nissim A, Knight AR, Whiteman M, Haigh R, Winyard PG. Oxidative stress in autoimmune rheumatic diseases. *Free Radic Biol Med*. 2018;125:3-14.
24. Kannan S. Free radical theory of autoimmunity. *Theor Biol Med Model*. 2006;3:22.
25. Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. *J Clin Invest*. 2009;119:1335-1349.
26. Chou MY, Hartvigsen K, Hansen LF, et al. Oxidation-specific epitopes are important targets of innate immunity. *J Intern Med*. 2008;263:479-488.
27. Ortiz-Hernandez GL, Sanchez-Hernandez ES, Casiano CA. Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions. *Autoimmun Highlights*. 2020;11(1): 3. doi:10.1186/s13317-020-0126-4
28. Wu C, Jain MR, Li Q, et al. Identification of novel nuclear targets of human thioredoxin 1. *Mol Cell Proteomics*. 2014;13:3507-3518. doi:10.1074/mcp.M114.040931
29. Józwiak J, Kasperczyk S, Tomasik T, et al. Design and rationale of a nationwide screening analysis from the LIPIDOGram2015 and LIPIDOGEn2015 studies. *Arch Med Sci*. 2020;16:1-13.
30. Erel O. A new automated colorimetric method for measuring total oxidant status. *Clin Biochem*. 2005;38:1103-1111.
31. Södergren E, Nourooz-Zadeh J, Berglund L, Vessby B. Re-evaluation of the ferrous oxidation in xylenol orange assay for the measurement of plasma lipid hydroperoxides. *J Biochem Biophys Methods*. 1998;37:137-146.
32. Jain SK. In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats. *J Clin Invest*. 1985;76:281-286.
33. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem*. 1979;95:351-358.
34. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. *Anal Biochem*. 1984;142:290-296.
35. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. *Clin Biochem*. 2004;37:277-285.
36. Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. *Ann Rheum Dis*. 2014;73:17-23.
37. Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEP-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective. *Ann Rheum Dis*. 2019;78:879-889.
38. WHO/Europe. Nutrition—body mass index—BMI. Accessed November 14, 2019. <http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi>
39. Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO expert consultation on waist circumference and waist-hip ratio. *Eur J Clin Nutr*. 2010;64:2-5.
40. Miyara M, Albesa R, Charuel J-L, et al. Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. *Clin Dev Immunol*. 2013;2013:703759.
41. Mutlu E, Eyigör M, Mutlu D, Gültekin M. Confirmation of anti-DFS70 antibodies is needed in routine clinical samples with DFS staining pattern. *Cent Eur J Immunol*. 2016;41:6-11.
42. Bizzaro N, Tonutti E, Tampona M, et al. Specific chemoluminescence and immunoabsorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. *Clin Chim Acta*. 2015;451:271-277. doi:10.1016/j.cca.2015.10.008
43. Bizzaro N, Tonutti E, Visentini D, et al. Antibodies to the lens and cornea in anti-DFS70-positive subjects. *Ann NY Acad Sci*. 2007;1107:174-183.
44. Carbone T, Pafundi V, Tramontano G, et al. Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort. *Sci Rep*. 2019;9:2177. doi:10.1038/s41598-019-38686-5
45. Bizzaro N, Tonutti E, Villalta D. Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: not an easy task! comment on the article by Mariz et al. *Arthritis Rheum*. 2011;63:4036-NaN7; author reply 4037. Published online 2011. doi:10.1002/art.30621
46. Damoiseaux J, von Mühlen CA, Garcia-De La Torre I, et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. *Autoimmun Highlights*. 2016;7:1-8.
47. Infantino M, Bizzaro N, Grossi V, Manfredi M. The long-awaited 'pseudo-DFS pattern'. *Expert Rev Clin Immunol*. 2019;15:445.
48. Gerling IC. Oxidative stress, altered-self and autoimmunity. *Open Autoimmun J*. 2009;1:33-36.
49. Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. *Autoimmun Rev*. 2008;7:567-573.
50. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. *Free Radic Biol Med*. 2010;48:749-762.
51. Kujoth GC, Hiona A, Pugh TD, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. *Science*. 2005;309:481-484. doi:10.1126/science.1112125
52. Tyurin VA, Tyurina YY, Ritov VB, et al. Oxidative lipidomics of apoptosis: quantitative assessment of phospholipid hydroperoxides in cells and tissues. *Methods Mol Biol*. 2010;610:353-374. doi:10.1007/978-1-60327-029-8_21
53. Ayaki M, Sueno T, Singh DP, Chylack LT Jr, Shinohara T. Antibodies to lens epithelium-derived growth factor (LEDGF) kill epithelial cells of whole lenses in organ culture. *Exp Eye Res*. 1999;69:139-142. doi:10.1006/exer.1999.0701
54. Ayaki M, Ohguro N, Azuma N, et al. Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. *Autoimmunity*. 2002;35:319-327. doi:10.1080/0891693021000003198